Association of soluble TREM2 with Alzheimer's disease and mild cognitive impairment: a systematic review and meta-analysis

被引:0
|
作者
Wang, Ruiqi [1 ]
Zhan, Yijun [1 ]
Zhu, Wenyan [1 ]
Yang, Qianwen [1 ]
Pei, Jian [1 ]
机构
[1] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Dept Acupuncture, Shanghai, Peoples R China
来源
关键词
soluble TREM2; Alzheimer's disease; mild cognitive impairment; neuroinflammation; meta-analysis; BIOMARKERS; EXPRESSION; MICROGLIA; INSIGHTS; VARIANT;
D O I
10.3389/fnagi.2024.1407980
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Objective Soluble triggering receptor expressed on myeloid cells 2 (sTREM2) is a potential neuroinflammatory biomarker linked to the pathogenesis of Alzheimer's disease (AD) and mild cognitive impairment (MCI). Previous studies have produced inconsistent results regarding sTREM2 levels in various clinical stages of AD. This study aims to establish the correlation between sTREM2 levels and AD progression through a meta-analysis of sTREM2 levels in cerebrospinal fluid (CSF) and blood. Methods Comprehensive searches were conducted in PubMed, Embase, Web of Science, and the Cochrane Library to identify observational studies reporting CSF and blood sTREM2 levels in AD patients, MCI patients, and healthy controls. A random effects meta-analysis was used to calculate the standardized mean difference (SMD) and 95% confidence intervals (CIs). Results Thirty-six observational studies involving 3,016 AD patients, 3,533 MCI patients, and 4,510 healthy controls were included. CSF sTREM2 levels were significantly higher in both the AD [SMD = 0.28, 95% CI (0.15, 0.41)] and MCI groups [SMD = 0.30, 95% CI (0.13, 0.47)] compared to the healthy control group. However, no significant differences in expression were detected between the AD and MCI groups [SMD = 0.09, 95% CI (-0.09, 0.26)]. Furthermore, increased plasma sTREM2 levels were associated with a higher risk of AD [SMD = 0.42, 95% CI (0.01, 0.83)]. Conclusion CSF sTREM2 levels are positively associated with an increased risk of AD and MCI. Plasma sTREM2 levels were notably higher in the AD group than in the control group and may serve as a promising biomarker for diagnosing AD. However, sTREM2 levels are not effective for distinguishing between different disease stages of AD. Further investigations are needed to explore the longitudinal changes in sTREM2 levels, particularly plasma sTREM2 levels, during AD progression. Systematic review registration https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024514593
引用
下载
收藏
页数:10
相关论文
共 50 条
  • [41] Gut microbiome characteristics in subjective cognitive decline, mild cognitive impairment and Alzheimer's disease: a systematic review and meta-analysis
    Chen, Guanlin
    Zhou, Xiaoqi
    Zhu, Yikang
    Shi, Wendian
    Kong, Li
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 (11) : 3568 - 3580
  • [42] A Systematic Review and Meta-Analysis of On-Road Simulator and Cognitive Driving Assessment in Alzheimer's Disease and Mild Cognitive Impairment
    Hird, Megan A.
    Egeto, Peter
    Fischer, Corinne E.
    Naglie, Gary
    Schweizer, Tom A.
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 53 (02) : 713 - 729
  • [43] The most prevalent rare coding variants of TREM2 conferring risk of Alzheimer's disease: A systematic review and meta-analysis
    Li, Rong
    Wang, Xia
    He, Pengfei
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 21 (04)
  • [44] Transcranial magnetic stimulation effects on cognitive enhancement in mild cognitive impairment and Alzheimer's disease: a systematic review and meta-analysis
    Yan, Yixin
    Tian, Minjie
    Wang, Tong
    Wang, Xixi
    Wang, Yingying
    Shi, Jingping
    FRONTIERS IN NEUROLOGY, 2023, 14
  • [45] Retinal Microvascular Changes in Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review, Meta-Analysis, and Meta-Regression
    Yeh, Tsai-Chu
    Kuo, Chun-Tung
    Chou, Yu-Bai
    FRONTIERS IN AGING NEUROSCIENCE, 2022, 14
  • [46] Markers for the detection of Lewy body disease versus Alzheimer’s disease in mild cognitive impairment: a systematic review and meta-analysis
    Marianna Ilarj Burgio
    Nicola Veronese
    Davide Sarà
    Carlo Saccaro
    Roberta Masnata
    Giusy Vassallo
    Angela Catania
    Giuseppina Catanese
    Christoph Mueller
    Lee Smith
    Ligia Juliana Dominguez
    Laura Vernuccio
    Mario Barbagallo
    Aging Clinical and Experimental Research, 36
  • [47] Markers for the detection of Lewy body disease versus Alzheimer's disease in mild cognitive impairment: a systematic review and meta-analysis
    Burgio, Marianna Ilarj
    Veronese, Nicola
    Sara, Davide
    Saccaro, Carlo
    Masnata, Roberta
    Vassallo, Giusy
    Catania, Angela
    Catanese, Giuseppina
    Mueller, Christoph
    Smith, Lee
    Dominguez, Ligia Juliana
    Vernuccio, Laura
    Barbagallo, Mario
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2024, 36 (01)
  • [48] Efficacy and Safety of Probiotics for the Treatment of Alzheimer's Disease, Mild Cognitive Impairment, and Parkinson's Disease: A Systematic Review and Meta-Analysis
    Xiang, Shuai
    Ji, Jin-Long
    Li, Sha
    Cao, Xi-Peng
    Xu, Wei
    Tan, Lan
    Tan, Chen-Chen
    FRONTIERS IN AGING NEUROSCIENCE, 2022, 14
  • [49] Ginkgo Biloba for Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Yang, Guoyan
    Wang, Yuyi
    Sun, Jin
    Zhang, Kang
    Liu, Jianping
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2016, 16 (05) : 520 - 528
  • [50] Association between Periodontitis and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis
    Lin, Jieling
    Pathak, Janak L.
    Shen, Yuqin
    Mashrah, Mubarak Ahmed
    Zhong, Xiaomei
    Chen, Jianwei
    Li, Zirui
    Xia, Junyi
    Liang, Yanling
    Zeng, Yangbin
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2024, 53 (01) : 37 - 46